INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8701, 0, 'Mitomycin', 'Hemorrhagic Disorders', 'The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency.  Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8702, 0, 'Mitomycin', 'Bone Marrow Failure Disorders', 'Mitomycin induces cumulative, delayed myelosuppression.  Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy.  Anemia occurs less frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8703, 0, 'Mitomycin', 'Kidney Diseases', 'Elevations in BUN and/or serum creatinine have been reported during mitomycin therapy.  Therapy with mitomycin should not be administered to patients with serum creatinine > 1.7 mg/dl.  Hemolytic Uremic Syndrome (HUS) has been reported during mitomycin therapy. The incidence of HUS appears to be increased in patients receiving total doses of mitomycin > 60 mg.  Blood product transfusion may exacerbate the symptoms of HUS.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8704, 21947, 'Miglitol', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8705, 21948, 'Miglitol', 'Diabetic Ketoacidosis', 'The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8706, 21947, 'Miglitol', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8707, 21948, 'Miglitol', 'Intestinal Diseases', 'The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption.  Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates.  Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8708, 21947, 'Miglitol', 'Kidney Diseases', 'Miglitol is eliminated primarily by the kidney.  Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with miglitol should be administered cautiously in patients with renal insufficiency.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8709, 21948, 'Miglitol', 'Kidney Diseases', 'Miglitol is eliminated primarily by the kidney.  Plasma miglitol levels in patients with renal impairment have been shown to proportionally increase relative to the degree of renal dysfunction.  However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted.  Therapy with miglitol should be administered cautiously in patients with renal insufficiency.  The manufacturer does not recommend its use in patients with significantly impaired renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8710, 0, 'Migalastat', 'Kidney Diseases', 'Migalastat is substantially excreted by the kidneys.  No dosage adjustment is required in patients with mild to moderate renal impairment (eGFR at least 30 mL/min/1.73 m2 and above).  Migalastat is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.  Systemic exposure was significantly increased in subjects with severe renal impairment (eGFR less than 30 mL/min/1.73 m2).  Migalastat has not been studied in patients with Fabry disease who have an eGFR less than 30 mL/min/1.73 m2.  Care is recommended when using this agent in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8711, 0, 'Miltefosine', 'Sjogren-Larsson Syndrome', 'The use of miltefosine is contraindicated in patients with Sjogren-Larsson syndrome.  Miltefosine undergoes metabolic cleavage in hepatocytes to release choline.  The fatty alcohol-containing fragment of miltefosine is then oxidized to palmitic acid, which enters the metabolism of fatty acids.  However, this oxidation is blocked in patients with Sjogren-Larsson syndrome, who have a genetic defect in fatty aldehyde dehydrogenase activity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8712, 0, 'Miltefosine', 'Liver Diseases', 'Elevations in liver transaminases (ALT, AST) and bilirubin were observed in clinical trials of miltefosine for the treatment of visceral leishmaniasis.  Patients with serum ALT or AST levels at least 3 times the upper limit of normal and bilirubin levels at least 2 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with liver dysfunction; caution is recommended.  Liver transaminases (ALT, AST) and bilirubin should be monitored during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8713, 0, 'Miltefosine', 'Kidney Diseases', 'Elevations in serum creatinine were observed in clinical trials of miltefosine for the treatment of cutaneous, mucosal, and visceral leishmaniasis.  Patients with serum creatinine or BUN levels at least 1.5 times the upper limit of normal were excluded from clinical trials.  The pharmacokinetics of miltefosine have not been studied in patients with renal dysfunction; caution is recommended.  Renal function should be monitored weekly during therapy and for 4 weeks after completion of therapy.  Abdominal pain, nausea, vomiting, and diarrhea are common side effects of miltefosine; patients should be advised to drink plenty of fluids to avoid dehydration (and, thus, the risk of kidney injury) and to seek medical attention if these gastrointestinal side effects are persistent or severe.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8714, 0, 'Miltefosine', 'Thrombocytopenia', 'Thrombocytopenia has been reported during treatment of visceral leishmaniasis, including with miltefosine.  Therapy with miltefosine should be administered cautiously in patients with preexisting thrombocytopenia.  Platelet counts should be monitored during therapy for visceral leishmaniasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8715, 229, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8716, 5890, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8717, 7509, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8718, 8215, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8719, 11343, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8720, 13593, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8721, 15379, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8722, 15412, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8723, 19585, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8724, 20186, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8725, 20187, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8726, 20196, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8727, 20197, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8728, 20210, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8729, 20216, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8730, 22799, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8731, 22801, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8732, 22802, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8733, 22803, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8734, 23414, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8735, 24398, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8736, 24743, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8737, 24745, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8738, 25791, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8739, 25792, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8740, 25811, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8741, 25812, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8742, 26586, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8743, 33210, 'Minoxidil (topical)', 'Scalp Dermatoses', 'In general, topically applied minoxidil is poorly absorbed from the normal, intact scalp.  However, alteration in scalp epidermal integrity (e.g., abrasion, sunburn, psoriasis) can increase percutaneous absorption with resultant systemic effects, including sodium and water retention, local or generalized edema, pericardial effusion, pericarditis, tamponade, tachycardia, and worsening or development of angina.  Therapy with minoxidil should be avoided in patients with diminished or altered scalp integrity that may lead to enhanced systemic absorption, particularly in the presence of underlying cardiovascular dysfunction or fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8744, 6693, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8745, 14737, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8746, 22757, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8747, 22758, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8748, 22759, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8749, 22760, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8750, 22761, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8751, 22762, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8752, 23184, 'Milnacipran', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8753, 6693, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8754, 14737, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8755, 22757, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8756, 22758, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8757, 22759, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8758, 22760, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8759, 22761, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8760, 22762, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8761, 23184, 'Milnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8762, 6693, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8763, 14737, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8764, 22757, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8765, 22758, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8766, 22759, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8767, 22760, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8768, 22761, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8769, 22762, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8770, 23184, 'Milnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8771, 6693, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8772, 14737, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8773, 22757, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8774, 22758, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8775, 22759, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8776, 22760, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8777, 22761, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8778, 22762, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8779, 23184, 'Milnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8780, 6693, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8781, 14737, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8782, 22757, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8783, 22758, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8784, 22759, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8785, 22760, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8786, 22761, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8787, 22762, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8788, 23184, 'Milnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8789, 6693, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8790, 14737, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8791, 22757, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8792, 22758, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8793, 22759, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8794, 22760, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8795, 22761, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8796, 22762, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8797, 23184, 'Milnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8798, 6693, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8799, 14737, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (8800, 22757, 'Milnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '', 'DDInter', 0);
